Table 1.
Discrete Statistics, Mean (SD) or count (%) for the comparison of baseline clinical and demographic data for placebo and pimozide treated groups.
| Variable | Treatment |
p-value | |
|---|---|---|---|
| Placebo (N = 28) Mean (SD) | Pimozide (N = 25) Mean (SD) | ||
| Age (Years) | 44.4 (8.7) | 45.5 (10.2) | .66 |
| Education (Years) | 11.8 (2.1) | 11.2 (2.3) | .38 |
| Age of Illness Onset (Years) | 18.5 (4.6) | 19.2 (4.2) | .58 |
| Clozapine Dose (mg/day) | 478.1 (150.2) | 518.8 (117.3) | .30 |
| Plasma Clozapine Concentration (ng/ml) | 555.5 (147.7) | 558.1 (152.5) | .95 |
| Duration of Clozapine Treatment (Months) | 20.8 (25.2) | 16.8 (14.7) | .53 |
| PANSS Total | 90.7 (16.0) | 82.9 (15.1) | .08 |
| PANSS Positive | 22.3 (4.9) | 21.0 (4.9) | .36 |
| PANSS Negative | 24.6 (6.4) | 21.9 (4.4) | .08 |
| PANSS General | 44.0 (8.1) | 40.0 (9.0) | .11 |
| SLOF Physical Functioning | 24.77 (.81) | 24.36 (.99) | .11 |
| SLOF Personal Care | 30.81 (2.56) | 30.28 (4.67) | .61 |
| SLOF Interpersonal Relationships | 22 (5.62) | 24.56 (4.19) | .07 |
| SLOF Social Acceptability | 32.85 (2.49) | 32.48 (3.14) | .64 |
| SLOF Activities | 39 (12) | 38.92 (10.48) | .97 |
| SLOF Work Skills | 17.08 (6.35) | 17.36 (5.05) | .86 |
| Variable | Count (%) | Count (%) | p-value |
| Gender | |||
| Female | 8 (29%) | 4 (16%) | .34 |
| Male | 20 (71%) | 21 (84%) | |
| Ethnicity | |||
| Asian | 1 (4%) | 0 (0%) | .04 |
| Black | 4 (14%) | 13 (52%) | |
| Hispanic | 6 (12%) | 5 (20%) | |
| White | 17 (61%) | 7 (28%) | |
| Treatment Setting | |||
| Inpatient | 19(68%) | 15(60%) | .47 |
| Outpatient | 9(32%) | 10(40%) | |
| Valproic Acid Treatment | |||
| No | 18 (64%) | 17 (68%) | .96 |
| Yes | 10 (36%) | 8 (32%) | |